Diversified Trust Co Sells 6,271 Shares of Globus Medical, Inc. $GMED

Diversified Trust Co cut its position in Globus Medical, Inc. (NYSE:GMED) by 40.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,140 shares of the medical device company’s stock after selling 6,271 shares during the period. Diversified Trust Co’s holdings in Globus Medical were worth $788,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Advisory Services Network LLC bought a new stake in shares of Globus Medical during the third quarter valued at approximately $26,000. EverSource Wealth Advisors LLC increased its stake in Globus Medical by 74.3% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock valued at $27,000 after purchasing an additional 197 shares in the last quarter. SBI Securities Co. Ltd. increased its stake in Globus Medical by 98.2% during the 4th quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock valued at $29,000 after purchasing an additional 167 shares in the last quarter. Parallel Advisors LLC raised its holdings in Globus Medical by 45.1% during the third quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock worth $32,000 after buying an additional 173 shares during the last quarter. Finally, Headlands Technologies LLC raised its holdings in Globus Medical by 485.4% during the second quarter. Headlands Technologies LLC now owns 761 shares of the medical device company’s stock worth $45,000 after buying an additional 631 shares during the last quarter. 95.16% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on GMED. Barclays raised their price objective on shares of Globus Medical from $118.00 to $123.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. Needham & Company LLC boosted their target price on shares of Globus Medical from $114.00 to $117.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Weiss Ratings restated a “hold (c+)” rating on shares of Globus Medical in a report on Wednesday, April 15th. Royal Bank Of Canada raised their price target on shares of Globus Medical from $115.00 to $120.00 and gave the company an “outperform” rating in a research report on Friday, May 8th. Finally, Zacks Research upgraded Globus Medical from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, March 3rd. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $105.00.

Globus Medical Price Performance

Shares of GMED stock opened at $82.37 on Thursday. The firm has a 50-day moving average of $83.95 and a 200-day moving average of $87.47. The company has a market cap of $11.18 billion, a P/E ratio of 19.16, a P/E/G ratio of 1.65 and a beta of 0.95. Globus Medical, Inc. has a one year low of $51.79 and a one year high of $101.40.

Globus Medical (NYSE:GMED) last released its quarterly earnings results on Thursday, May 7th. The medical device company reported $1.12 earnings per share for the quarter, beating analysts’ consensus estimates of $0.92 by $0.20. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. The company had revenue of $759.85 million for the quarter, compared to analyst estimates of $740.35 million. During the same period last year, the firm earned $0.68 earnings per share. The firm’s revenue was up 27.0% on a year-over-year basis. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. As a group, research analysts expect that Globus Medical, Inc. will post 4.74 earnings per share for the current fiscal year.

Trending Headlines about Globus Medical

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Zacks Research lifted multiple earnings forecasts for Globus Medical, signaling improving expectations for future profitability and supporting the stock. Globus Medical stock page
• Positive Sentiment: The analyst firm reiterated a Strong-Buy rating, which may reinforce investor confidence in GMED. Globus Medical stock page
• Neutral Sentiment: One article discussed large executive and median employee pay increases in 2025, which could draw attention to compensation practices but does not appear to be a major operating update. Globus Medical compensation article
• Neutral Sentiment: Another article framed the company’s prior earnings beat and foreign exchange pressures as factors that may affect the investment case, but it did not introduce a fresh negative catalyst. Globus Medical earnings/FX article

Insider Activity

In related news, Director David D. Davidar sold 25,000 shares of the stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $80.76, for a total transaction of $2,019,000.00. Following the completion of the sale, the director directly owned 510,175 shares of the company’s stock, valued at approximately $41,201,733. This trade represents a 4.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 18.38% of the stock is currently owned by corporate insiders.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.